Please login to the form below
Matt Regan named AbbVie’s general manager in UK
Was formerly general manager of Abbott in Norway
AbbVie, the new independent biopharma spin-out from Abbott, has appointed Matt Regan as general manager of its UK business.
Regan was formerly general manager for Abbott in Norway and will now oversee the new firm's UK presence as it establishes itself as a separate research-based pharma company.
During his time in Norway, Regan set up and led the Norwegian Industry Association's Biosimilars committee, and helped establish Abbott as one of the fastest growing pharma companies in the region.
He has been with Abbott for more than a decade, serving in several European roles, including as regional director, North Europe for Abbott Diabetes Care, and general manager of the Baltic States for Abbott.
Featured jobs
- Medical Writer, Healthcare Advertising
-
£35 - £45, 000 benefits
- Senior Account Director or Business Unit Director, Healthcare Ad...
-
C£60, 000 – £70, 000 benefits
- Senior Strategic Planner, Healthcare Brand Communications, Londo...
-
Competitive Salary
-
Scientific Engagement Director
-
Salary will be dependant on experience
- Account Director, Training & Medical Communications, London
-
Competitive Salary
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Medical Writer - Medical Communications
-
£30, 000 - £40, 000 according to skills and experience plus benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Science Writer – Healthcare Advertising
-
Salary TBC
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
Subscribe to our email news alerts
- Roche starts new late-stage trials of Alzheimer’s candidate
- AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
- Moving annual total (MAT)
- Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat
- More impressive data from Bluebird’s gene therapy in thalassemia and sickle cell disease
- Key success factor (KSF)
- The playbook of a ‘reluctant creative’
- Chiesi targets patient adherence via mobile app
- PEGASUS OPENS THE HEALTHCARE INSIGHTS STAGE AT CANNES LIONS
- May earmarks £20bn for the NHS - but experts say it's not enough
- Daily Brief, CAR-T update, new leukaemia treatments, universal flu hope and more
- New trial results suggest CAR-T effects are durable in lymphoma
PMHub
Cello Health
Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...
Latest intelligence
- Australian Flu and the dilemma of naming diseases
- ...
- Wearables and Healthcare
- What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
- What does a future-proof rep look like?
- Businesses can no longer afford to push ahead with the traditional Key Account Management model....
Quick links
Infographics
